Nancy G. Cocozza is Independent Director of the Company. became a director of Vermillion in August 2018. She is a member of our Audit Committee and is also a member of our Compensation Committee. Ms. Cocozza retired in June 2018 from the position of President of the Medicare Business for Aetna, where she was responsible for Aetna’s Medicare strategy, growth and operating results; she led a team that, at the time of her retirement, served more than 4 million Medicare members nationwide through a robust portfolio of Medicare Advantage plans, Medicare prescription drug plans and Medicare Supplement plans. Prior to Aetna, Ms. Cocozza was Executive Vice President at HealthMarkets, an individual market health insurance provider, where she led the Medicare division. She also led the government insurance programs at Coventry Health Care. Ms. Cocozza began her career at Aetna, where she spent 16 years building and leading various commercial managed care operations. Ms. Cocozza holds a B.S. degree in accounting from Thomas Jefferson/Philadelphia University. Our Board has determined that based upon Ms. Cocozza’s extensive experience in the health industry, including her financial and Medicare reimbursement background, she has the qualifications and skills to serve as a member of our Board, a member of our Audit Committee, a member of our Compensation Committee and a member of our Strategy Committee.
As the Independent Director of Vermillion, the total compensation of Nancy Cocozza at Vermillion is $143,500. There are 2 executives at Vermillion getting paid more, with Valerie Palmieri having the highest compensation of $941,832.
Nancy Cocozza is 58, she's been the Independent Director of Vermillion since 2018. There are 4 older and 1 younger executives at Vermillion. The oldest executive at Vermillion, Inc. is James Burns, 73, who is the Independent Director.
Nancy's mailing address filed with the SEC is C/O VERMILLION, INC., 12117 BEE CAVES RD, BLDG 3-100, AUSTIN, TX, 78738.
Over the last 17 years, insiders at Vermillion have traded over $1,008,376 worth of Vermillion stock and bought 29,557,130 units worth $34,088,488 . The most active insiders traders include Jack W Schuler, Henri George Schuler e Larry Noracle Partners Lp F.... On average, Vermillion executives and independent directors trade stock every 59 days with the average trade being worth of $1,572,028. The most recent stock trade was executed by Robert Harry Beechey on 15 November 2019, trading 5,000 units of VRML stock currently worth $3,550.
Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Vermillion executives and other stock owners filed with the SEC include: